Invossa Gene Therapy Controversy Grows As Government, Patients Take Action
Executive Summary
While the eventual fate of Kolon Life’s gene therapy Invossa is still undecided after interim results from an ongoing probe into its composition, controversy over the product is growing as patients seek compensation from the company and government, and calls grow for a wider investigation.
You may also be interested in...
South Korea Invossa Incident Raises Suspicions About Regulators, Sponsor At Local Forum
Controversy over Kolon Life Science’s gene therapy Invossa continue to escalate with participants in a recent forum led by the country’s progressive political party raising suspicions over the company and drug authorities; they called for a re-examination of the current drug approval and development process and halt on further easing of regulations.
What Can Korea Learn From The Invossa Trial And Error Case?
South Korea, which has recently delayed the political passage of a cutting-edge regenerative medicine and biologics act, should learn from the latest unprecedented incident involving Kolon Life Science’s cell and gene therapy Invossa, and pre-emptively make preparations and guidelines to better deal with such pioneering medicines, an industry expert tells Scrip.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.